miRagen Therapeutics Achieves First Milestone in Strategic Alliance with Servier

Servier, a privately-run French research-based pharmaceutical company and a major player in Europe and emerging markets having expertise in the development of treatments for cardiovascular diseases, and miRagen Therapeutics, Inc., a biopharmaceutical company developing innovative microRNA-based therapeutics, announced today that Servier has elected to add a new target as part of its existing agreement for advancing the research, development and commercialization of microRNA-based drug candidates for the treatment of cardiovascular disease. With this selection, Servier and miRagen now have three microRNA programs under development.

“Our selection of a third target is indicative of the strength of our partnership with miRagen, as well as our shared commitment to develop microRNA-based therapies for the treatment of cardiovascular disease,” said Dr. Jean-Paul Vilaine, Head of Servier’s Cardiovascular Research Unit. “We look forward to our continued collaboration to advance promising drug candidates.”

For Dr. Jean-Philippe Seta, Chief Executive Officer of Servier, “Micro-RNA is now the gateway to acting at the deepest level of gene expression regulation, with exciting prospects of major developments in the treatment of cardiovascular disease.”

“The achievement of this milestone further validates the potential of miRagen’s platform in the development of disease-modifying drug candidates,” said William S. Marshall, Ph.D., President and Chief Executive Officer of miRagen Therapeutics, Inc. “We remain deeply committed to the discovery and advancement of microRNA-based therapeutics, and we anticipate that our partnership with Servier will yield life-changing treatment options for patients in need.”